Capricor Therapeutics (NASDAQ:CAPR) Shares Up 5.2% – Here’s What Happened

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) rose 5.2% during trading on Monday . The company traded as high as $18.94 and last traded at $18.69. Approximately 839,585 shares changed hands during trading, a decline of 22% from the average daily volume of 1,080,003 shares. The stock had previously closed at $17.77.

Wall Street Analyst Weigh In

CAPR has been the topic of a number of recent analyst reports. Oppenheimer restated an “outperform” rating and set a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Cantor Fitzgerald restated an “overweight” rating and set a $8.00 price target on shares of Capricor Therapeutics in a research report on Friday, September 20th. Maxim Group boosted their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Capricor Therapeutics in a report on Wednesday, October 9th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $22.60.

Capricor Therapeutics Trading Up 10.2 %

The business’s fifty day moving average is $7.44 and its 200 day moving average is $6.07. The firm has a market capitalization of $626.15 million, a P/E ratio of -21.90 and a beta of 4.01.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The firm had revenue of $3.97 million during the quarter, compared to analysts’ expectations of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. As a group, sell-side analysts predict that Capricor Therapeutics Inc will post -1.13 earnings per share for the current fiscal year.

Insider Transactions at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the company’s stock in a transaction dated Friday, September 20th. The shares were acquired at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the transaction, the insider now directly owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 12.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after purchasing an additional 200,499 shares in the last quarter. Renaissance Technologies LLC grew its position in Capricor Therapeutics by 158.7% during the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 84,350 shares in the last quarter. Marshall Wace LLP purchased a new position in Capricor Therapeutics during the second quarter valued at approximately $426,000. Bank of New York Mellon Corp grew its position in Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after purchasing an additional 9,040 shares in the last quarter. Finally, Rhumbline Advisers purchased a new position in Capricor Therapeutics during the second quarter valued at approximately $147,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.